Your IP Is Sitting in a Freezer Somewhere, And Your CRA Doesn’t Know Where
Decentralized supply management is breaking traditional cold-chain oversight. Here's what DSM failures cost sites in enrollment ramp and budget...
The VIRAGE Trial Cracked the Pancreatic Cancer Wall. Now the Hard Question Is Whether the Field Can Read the Blueprint.
VCN-01 plus gemcitabine/nab-paclitaxel improved OS in metastatic pancreatic cancer. The VIRAGE Phase 2b design shows what rigorous endpoint selection...
Clinical Trials Struggle to Recruit Undiagnosed Patients Without Diagnostic Coverage
Clinical trials recruit faces barriers when patients lack diagnoses. Diagnostic coverage gaps exclude 25M Americans from research participation.
EP-104GI Maintains 64% Remission Rate at 52 Weeks in Eosinophilic Esophagitis Trial
EP-104GI maintains 64% remission rate at 52 weeks in eosinophilic esophagitis trial, offering a single-procedure alternative to daily therapy.
Phathom Opens Phase 3 Trial of On-Demand Vonoprazan for Non-Erosive GERD
Phathom opens Phase 3 trial testing vonoprazan for non-erosive GERD as an on-demand treatment, potentially changing how the drug...
Cartesian Descartes-08 Shows Retreatment Response in MG Patients
Cartesian's Descartes-08 retreatment data shows MG patients can receive repeat doses with sustained response, informing Phase 3 dosing strategy.
Immix’s NXC-201 achieves 89% complete response rate in AL amyloidosis trial
Immix's NXC-201 achieves 89% complete response rate in Phase 2 AL amyloidosis trial, with 40 of 45 patients showing...
Dyne’s z-basivarsen shows 4.8% muscle strength improvement at one year in DM1 trial
Dyne's z-basivarsen shows 4.8% muscle strength improvement at one year in DM1 trial, signaling potential clinical benefit in a...
Giredestrant cuts disease progression risk 44% in ER-positive breast cancer
Giredestrant cuts disease progression risk 44% in ER-positive breast cancer versus standard endocrine therapy in phase III evERA trial...
Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution
Moleculin closed Part A enrollment at 89 subjects in its pivotal AML MIRACLE trial. Here's what site directors and...